Literature DB >> 20100794

Comparison of the PHQ-9 and CES-D depression scales in systemic sclerosis: internal consistency reliability, convergent validity and clinical correlates.

Katherine Milette1, Marie Hudson, Murray Baron, Brett D Thombs.   

Abstract

OBJECTIVE: The reported rates of depressive symptoms in patients with SSc are high. The Center for Epidemiologic Studies Depression Scale (CES-D) is the only measure of depressive symptoms validated for SSc patients. The objective of this study was to assess the internal consistency reliability, convergent validity and strength of association with clinical correlates of the 9-item version of the Patient Health Questionnaire depression scale (PHQ-9) compared with the CES-D in SSc.
METHODS: We conducted a cross-sectional, multicentre study of 566 SSc patients who were assessed with the PHQ-9 and CES-D scales, and through clinical histories and medical examinations. Internal consistency reliability was assessed with Cronbach's alpha, convergent validity with Pearson's correlation and the relationship of socio-demographic and clinical variables with the PHQ-9 and CES-D scores using multiple linear regression.
RESULTS: Scale reliability was good for the PHQ-9 (alpha = 0.87) and similar to the CES-D (alpha = 0.90). Correlations of the PHQ-9 total score were -0.68 with mental health, -0.43 with physical health, 0.44 with disability, 0.40 with pain and 0.79 with fatigue, which were all in the expected direction and similar to the results with the CES-D. Regression coefficients of clinical correlates did not differ significantly between models using the PHQ-9 and CES-D.
CONCLUSION: The PHQ-9 is reliable and valid for use as a measure of depressive symptom severity in patients with SSc and performs similarly to the CES-D. However, the PHQ-9 is advantageous because it is half the length of the CES-D, easily administered and scored, and is increasingly used across many patient groups for assessment in research and clinical settings.

Entities:  

Mesh:

Year:  2010        PMID: 20100794     DOI: 10.1093/rheumatology/kep443

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  41 in total

1.  Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease.

Authors:  Noelle E Carlozzi; Siera Goodnight; Anna L Kratz; Julie C Stout; Michael K McCormack; Jane S Paulsen; Nicholas R Boileau; David Cella; Rebecca E Ready
Journal:  J Huntingtons Dis       Date:  2019

2.  Blood cadmium and depressive symptoms: Confounded by cigarette smoking.

Authors:  Danielle E Kostrubiak; Caterina Vacchi-Suzzi; Dylan M Smith; Jaymie R Meliker
Journal:  Psychiatry Res       Date:  2017-07-10       Impact factor: 3.222

3.  Physical Activity, Gender Difference, and Depressive Symptoms.

Authors:  Jun Zhang; Steven T Yen
Journal:  Health Serv Res       Date:  2015-01-28       Impact factor: 3.402

4.  Health disparities in police officers: comparisons to the U.S. general population.

Authors:  Tara A Hartley; Cecil M Burchfiel; Desta Fekedulegn; Michael E Andrew; John M Violanti
Journal:  Int J Emerg Ment Health       Date:  2011

5.  Do Symptoms of Depression Interact with Substance Use to Affect HIV Continuum of Care Outcomes?

Authors:  Anthony T Fojo; Catherine R Lesko; Keri L Calkins; Richard D Moore; Mary E McCaul; Heidi E Hutton; William C Mathews; Heidi Crane; Katerina Christopoulos; Karen Cropsey; Michael J Mugavero; Kenneth Mayer; Brian W Pence; Bryan Lau; Geetanjali Chander
Journal:  AIDS Behav       Date:  2019-03

6.  New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN).

Authors:  Brett D Thombs; Lisa R Jewett; Shervin Assassi; Murray Baron; Susan J Bartlett; Angela Costa Maia; Ghassan El-Baalbaki; Daniel E Furst; Karen Gottesman; Jennifer A Haythornthwaite; Marie Hudson; Ann Impens; Annett Korner; Catarina Leite; Maureen D Mayes; Vanessa L Malcarne; Sarosh J Motivala; Luc Mouthon; Warren R Nielson; Diane Plante; Serge Poiraudeau; Janet L Poole; Janet Pope; Maureen Sauve; Russell J Steele; Maria E Suarez-Almazor; Suzanne Taillefer; Cornelia H van den Ende; Erin Arthurs; Marielle Bassel; Vanessa Delisle; Katherine Milette; Allison Leavens; Ilya Razykov; Dinesh Khanna
Journal:  Clin Exp Rheumatol       Date:  2012-05-29       Impact factor: 4.473

7.  Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study.

Authors:  Linda Kwakkenbos; Brett D Thombs; Dinesh Khanna; Marie-Eve Carrier; Murray Baron; Daniel E Furst; Karen Gottesman; Frank van den Hoogen; Vanessa L Malcarne; Maureen D Mayes; Luc Mouthon; Warren R Nielson; Serge Poiraudeau; Robert Riggs; Maureen Sauvé; Fredrick Wigley; Marie Hudson; Susan J Bartlett
Journal:  Rheumatology (Oxford)       Date:  2017-08-01       Impact factor: 7.580

8.  A Multicomponent Intervention to Improve Primary Care Provider Adherence to Chronic Opioid Therapy Guidelines and Reduce Opioid Misuse: A Cluster Randomized Controlled Trial Protocol.

Authors:  Karen E Lasser; Christopher Shanahan; Victoria Parker; Donna Beers; Ziming Xuan; Orlaith Heymann; Allison Lange; Jane M Liebschutz
Journal:  J Subst Abuse Treat       Date:  2015-07-15

9.  Establishing a common metric for depressive symptoms: linking the BDI-II, CES-D, and PHQ-9 to PROMIS depression.

Authors:  Seung W Choi; Benjamin Schalet; Karon F Cook; David Cella
Journal:  Psychol Assess       Date:  2014-02-17

10.  History of opioid use as a risk factor for current use and mental health consequences among retired National Football League athletes: A 9-year follow-up investigation.

Authors:  Zachary L Mannes; Eugene M Dunne; Erin G Ferguson; Linda B Cottler; Nicole Ennis
Journal:  Drug Alcohol Depend       Date:  2020-08-28       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.